Table 2.
Summary of findings- Lasmiditan 200 mg is compared to Lasmiditan 100 mg in adult patients with migraine and cardiovascular risk factors
| Outcomes | Groups | Effects | Number of participants (Studies) | Certainty of the evidence (Grade) | ||
|---|---|---|---|---|---|---|
| Lasmiditan 200 mg | Lasmiditan 100 mg | Relative (95% CI) | Absolute (95% CI) | |||
| Headache pain free at 2 h | 77% higher | 23% lower | OR 0.77 (0.64-0.92) | 52 fewer per 1,000 (from 84 fewer to 17 fewer) | 2,081 (2 RCTs)[19,20] | ⨁⨁⨁⨁ HIGHa |
| MBS free at 2 h | 92% higher | 8% lower | OR 0.92 (0.76-1.10) | 20 fewer per 1,000 (from 65 fewer to 23 more) | 1,933 (2 RCTs)[19,20] | ⨁⨁⨁⨁ HIGHa |
| Sustained pain freedom at 24 h | 75% higher | 25% lower | OR 0.75 (0.61-0.93) | 36 fewer per 1,000 (from 57 fewer to 10 fewer) | 2,253 (2 RCTs)[19,20] | ⨁⨁⨁⨁ HIGHa |
| Headache relief at 2 h | No significant association between dose and event | No significant association between dose and event | OR 1.00 (0.84-1.18) | 0 fewer per 1,000 (from 42 fewer to 38 more) | 2,253 (2 RCTs)[19,20] | ⨁⨁⨁⨁ HIGHa |
| Disability level at 2 h (Not at all) | 93% higher | 7% lower | OR 0.93 (0.78-1.10) | 16 fewer per 1,000 (from 52 fewer to 21 more) | 2,253 (2 RCTs)[19,20] | ⨁⨁⨁⨁ HIGHa |
| Global Impression of change at 2 h (Very much better) | 90% higher | 10% lower | OR 0.90 (0.70-1.1.6) | 10 fewer per 1,000 (from 31 fewer to 16 more | 2,253 (2 RCTs)[19,20] | ⨁⨁⨁⨁ HIGHa |
Kuca et al. and Goadsby et al. showed no serious study limitations and in Kuca et al. blinding of participants and personnel were unclear. MBS: Most Bothersome Symptoms; CI: Confidence interval; OR: Odds ratio; RCT: Randomized Controlled Trial